Oprelvekin is an innovative therapeutic agent used to stimulate platelet production in patients experiencing thrombocytopenia, often due to chemotherapy. This cytokine therapy enhances the proliferation and maturation of megakaryocytes, the precursor cells to platelets, thereby increasing platelet counts and reducing the need for platelet transfusions. Amoytop Biotech's Oprelvekin is formulated to provide high efficacy and safety, offering a significant improvement in the management of thrombocytopenia. By boosting platelet production, Oprelvekin helps to minimize bleeding risks and supports the continuation of essential cancer treatments. Our commitment to advancing patient care through innovative biotechnologies is exemplified in the development of Oprelvekin, which addresses a critical need in oncology supportive care.
Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
